

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/266507 A1

(51) International Patent Classification:

A61M 1/36 (2006.01) C07K 1/22 (2006.01)
B01J 20/32 (2006.01) C07K 14/705 (2006.01)
C07K 14/525 (2006.01)

(21) International Application Number:

PCT/US2022/034099

(22) International Filing Date:

17 June 2022 (17.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/211,709 17 June 2021 (17.06.2021) US

(71) Applicant: IMMUNICOM, INC. [US/US]; 6048 Cornerstone Court West, Suite D, San Diego, California 92121 (US).

(72) Inventors: MATHO, Michael; c/o Immunicon, Inc., 6048 Cornerstone Court West, Suite D, San Diego, California 92121 (US). JOSEPHS, Steven F.; c/o Immunicon, Inc., 6048 Cornerstone Court West, Suite D, San Diego, California 92121 (US). MARLEAU, Annette; c/o Immunicon, Inc., 6048 Cornerstone Court West, Suite D, San Diego, California 92121 (US).

(74) Agent: BEDGOOD, Robert M.; c/o Pillsbury Winthrop, P.O. BOX 10500, McLean, Virginia 22101 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MODIFIED TNF AS A CAPTURE LIGAND




Figure 4

(57) Abstract: A column is disclosed for removal of sTNF-R2 from a body fluid. The column has a compartment, an inlet coupled to the compartment and configured to receive the body fluid, and a substrate disposed within the compartment. A capture ligand is coupled to the substrate and has a modified sequence with an amino acid substitution in a reference sequence that includes a portion of a natural TNF sequence. The modified sequence has an affinity for the sTNF-R2 that is greater than an affinity of the reference sequence for the sTNF-R2.



WO 2022/266507 A1